Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several core facts align with the label (indications, IL-17A mechanism, general infection/hypersensitivity precautions, subcutaneous administration only, and general TB/immunizations warnings). However, multiple psoriatic arthritis dosing claims are inconsistent with the provided label excerpts, including the lack of weight-based dosing for PsA, incorrect induction/maintenance schedule details, and unsupported/incorrect dose adjustment logic.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a biologic medication approved by the FDA for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Supported for indications: plaque psoriasis (1.1), psoriatic arthritis (1.2), ankylosing spondylitis (1.3).
Cosentyx works by blocking the action of interleukin-17A (IL-17A).
Supported: selectively binds to IL-17A and inhibits its interaction with IL-17 receptor (12.1).
Cosentyx may interact with other medications, such as immunosuppressants and biologics.
Partially supported/weak: label describes monitoring upon initiation/discontinuation and considerations for CYP450 substrate dosing adjustment (7), but does not specifically list immunosuppressants/biologics as examples in the provided excerpt.
Patients should be monitored for signs of adverse events such as injection-site reactions, fatigue, and headaches.
Partially supported/weak: label emphasizes monitoring (e.g., infections/TB) and adverse reactions are discussed, but the specific examples (injection-site reactions, fatigue, headaches) are not present in the provided excerpts.
Unsupported Statements
The recommended dose of Cosentyx for psoriatic arthritis is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4.
The provided PsA adult dosing excerpt states 150 mg at Weeks 0–4 with loading (and every 4 weeks thereafter), with possible increase to 300 mg if active PsA persists; it does not state 300 mg is the recommended PsA induction dose.
After the induction phase, Cosentyx is administered as maintenance doses of 300 mg subcutaneously every 4 weeks for psoriatic arthritis.
The provided PsA adult dosing excerpt lists maintenance 150 mg every 4 weeks (with or without loading) and considers increasing to 300 mg every 4 weeks only if the patient continues to have active PsA; it does not state 300 mg is standard maintenance.
Dose adjustments may be necessary in patients with psoriatic arthritis who experience adverse events.
The provided label excerpt does not describe dose adjustment for PsA due to adverse events.
Dose adjustments may be necessary in patients with psoriatic arthritis who have inadequate response to treatment.
While the label excerpt does mention considering an increase to 300 mg if active PsA continues, it does not support the generalized statement about dose adjustments for inadequate response as written.
A recommended dose adjustment for psoriatic arthritis includes reducing the Cosentyx dose to 150 mg administered subcutaneously every 4 weeks.
The provided label excerpt discusses increasing to 300 mg when active PsA persists, not reducing from 300 mg to 150 mg as a recommended adjustment.
A recommended dose adjustment for psoriatic arthritis includes interrupting Cosentyx treatment for up to 12 weeks, then resuming at the original dose.
No such interruption window (e.g., up to 12 weeks) or resumption rule is present in the provided PsA dosing excerpt.
The recommended dose of Cosentyx for psoriatic arthritis is based on patient weight.
The provided PsA adult dosing excerpt does not describe weight-based dosing for PsA (weight-based dosing is shown for plaque psoriasis in the provided excerpt).
Patients weighing 100 kg or more should receive 300 mg Cosentyx.
No weight-based dosing thresholds for PsA (e.g., 100 kg) are supported by the provided PsA dosing excerpt.
Patients weighing less than 100 kg should receive 150 mg Cosentyx.
No weight-based dosing thresholds for PsA (e.g., <100 kg) are supported by the provided PsA dosing excerpt.
Cosentyx has been shown to be effective in treating psoriatic arthritis with significant improvements in symptoms and quality of life.
Efficacy is supported in general (14.3 references greater clinical response at Week 24), but the specific phrasing 'quality of life' and 'significant improvements' is not directly supported by the provided excerpts.
Cosentyx (secukinumab) is a biologic medication approved by the FDA for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Biologic characterization is not explicitly stated in the provided excerpts (though secukinumab is described as an IL-17A antagonist). The indication portion is supported; the 'biologic' framing is not verifiable from the supplied text.
Contradictions
High
AI Statement
The recommended dose of Cosentyx for psoriatic arthritis is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4.
Label Reference
PsA adult dosing excerpt (2.4): with a loading dosage is 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; consider increasing to 300 mg every 4 weeks if active PsA continues.
High
AI Statement
After the induction phase, Cosentyx is administered as maintenance doses of 300 mg subcutaneously every 4 weeks for psoriatic arthritis.
Label Reference
PsA adult dosing excerpt (2.4): recommended dosage includes 150 mg every 4 weeks (with or without loading) and consider increasing to 300 mg every 4 weeks if active PsA persists.
Moderate
AI Statement
The recommended dose of Cosentyx for psoriatic arthritis is based on patient weight.
Label Reference
Provided PsA adult dosing excerpt (2.4) describes fixed 150 mg (and possible increase to 300 mg) regimens; weight-based dosing is shown for plaque psoriasis (2.3) but not for PsA in the supplied text.
Important Omissions
Pre-treatment evaluation for TB (active or latent) and that initiation is not recommended in active TB; latent TB treatment should be initiated prior to starting; also monitoring during/after treatment.
Importance:
Moderate
Immunization guidance: consider completing age-appropriate immunizations prior to therapy; avoid live vaccines.
Importance:
Moderate
Serious hypersensitivity management: immediately discontinue administration and initiate appropriate therapy for anaphylaxis/serious allergic reactions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Primary risk stems from multiple psoriatic arthritis dosing inaccuracies (wrong induction/maintenance dosing and unsupported weight-based thresholds), which could lead to inappropriate dosing. Other safety-related statements (monitoring/immunologic mechanism) are partially aligned but do not correct the dosing issues.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Psoriatic arthritis dosing claims (induction/maintenance 300 mg schedule, dose adjustments including reduction/interruption for up to 12 weeks, and weight-based dosing with 100 kg threshold) are not supported and/or conflict with the provided FDA label excerpts for PsA.
Suggested Improvement
Align PsA dosing to the provided label excerpt: 150 mg induction with loading (Weeks 0–4) and 150 mg every 4 weeks thereafter, with consideration to increase to 300 mg every 4 weeks if active PsA persists; remove weight-based dosing thresholds and the unsupported 12-week interruption recommendation.